Spots Global Cancer Trial Database for Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

Official Title: A Phase II Trial of Taxotere, Cisplatin, and Irinotecan in Advanced Esophageal and Gastric Cancer

Study ID: NCT00165464

Conditions

Esophageal Cancer

Gastric Cancer

GE Junction Cancer

Interventions

Taxotere

Cisplatin

Irinotecan

Study Description

Brief Summary: This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the patients cancer.

Detailed Description: * Taxotere, cisplatin and irinotecan will be administered to the patient once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks). * Patients will also receive corticosteroids, intravenous hydration and anti-emetic therapy prior to each treatment. * A physical exam and bloodwork will be done each week of the treatment and every 2 cycles, reassessment of the tumor by the same imaging method to determine the baseline size will be conducted. * Patients will remain on the study unless disease progression or intolerable toxicity occur.